The CBD Dialectic in Mental Health: Benign and Powerful?

Psychiatr Serv. 2020 Jan 1;71(1):2-3. doi: 10.1176/appi.ps.201900394. Epub 2019 Oct 23.
No abstract available

Keywords: Drug treatment/psychopharmacology; FDA; Public Health; Public education; cannabis.

MeSH terms

  • Cannabidiol / adverse effects
  • Cannabidiol / pharmacology*
  • Drug Approval
  • Drug Labeling / standards
  • Humans
  • Mental Disorders / chemically induced
  • Mental Disorders / drug therapy
  • Risk
  • United States
  • United States Food and Drug Administration

Substances

  • Cannabidiol